In a Hellenic cohort of MS patients, a high proportion showed peripheral T cell proliferation responses to hMOG35-55, as well as other myelin peptide antigens, across different HLA-DRB1 genotypes. Here, HLA-DRB1 is linked to myeloid sarcoma.